A Comperative Study on Health Sector in South Asia and Middle East Countries (Clinical Trial Studies) by Kolambil, Said Alavi & Jat, Rakesh Kumar
Kolambil et al                                                                                                 Journal of Drug Delivery & Therapeutics. 2019; 9(4-s):1101-1106 
ISSN: 2250-1177                                                                                  [1101]                                                                                 CODEN (USA): JDDTAO 
Available online on 25.08.2019 at http://jddtonline.info 
Journal of Drug Delivery and Therapeutics 
Open Access to Pharmaceutical and Medical Research 
© 2011-18, publisher and licensee JDDT, This is an Open Access article which permits unrestricted 
non-commercial use, provided the original work is properly cited 
Open  Access                                                                                                                                                     Research Article 
A Comperative Study on Health Sector in South Asia and Middle East 
Countries (Clinical Trial Studies) 
Said Alavi Kolambil*, Dr Rakesh Kumar Jat 
Institute of Pharmacy, Shri Jagdishprasad Jhabarmal Tibrewala Uinversity Vidya Nagari, Chudela Jhunjhunu, India 
 
ABSTRACT 
Pharmaceutical industries found suitable option in conducting clinical trial in  south Asia  and Middle East countries due less cost compare to 
western countries, pool of patient, and supported by highly infrastructural hospital, well trained staffs, liberalized policy  of the concerned 
government.  (E.g. in India), however once the products were succeeded, it denied access to the common man in affordable rate. the studies 
conducted on 463 participant from the region of middle east and from south Asian countries This studies revealed that there is a positive and 
highly correlation on fraudulent activities in clinical trial due to lack of ethical obligation and professional standards and on by scarcity of state 
and local law, shortage of tracking facility which encouraged this nefarious situation, even for the lawsuits,  victim worried to comes forward. 
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INTRODUCTION 
The fruitfulness of clinical trial considered as morally 
acceptable and beneficial to large in achieving long-sought 
medical gains. But some researchers conduct experiments 
without their knowledge and found to fail to disclose the 
facts which were known and obvious. The person on 
financial crisis from the region of south Asian and African 
counterparts, forced in to participate on clinical trial triage, 
most of them illiterate, this gullible person’s grievance often 
neglected in later follow-up procedures. Apart from this 
researchers can make quick prediction, biased decisions, 
finally prejudiced judgment about the overwhelming 
information which were encountered on his studies, recently 
lot of pharmaceutical products withdrawn from the market 
clearly supports above statement. The following description 
clearly supported the above facts, Elizabeth Loder (2017) 
reviewed research article around four year’s data in BMJ 
shows success of trial registration sponsored by private 
industries compare to public one. Here the pharmaceutical 
industries and medical equipment innovators aimed to 
retain status of the company. In 2017 USA alone data shows 
such national institute of health along with 20 countries 
registered for the sake of prospective terms instead of 
evaluating, proceeding on relevant topics. The author 
explained failure on registration on clinical trial due to lack 
of familiarity on the right of patient, muddled responsible 
authorities for this, misconception regarding what 
composed in clinical trials and so on. Here author arrived 
conclusion on ICMJE (Recommendations for the conduct, 
Reporting, Editing, and Publication of Scholarly work in 
medical journal) primarily any criteria for registration 
whether it upgraded or executed in trial system and 
secondly characteristics of health care providers’ 
accustomed such as medical error, omission involved on 
proceedings and so on. There is no universal standard for 
publishing clinical trial article; here some of the journal put 
forward on prospective terms, accountable, and adhered on 
standardized protocol. Others does not needed such 
yardstick (e.g. Ethic committee approval) to publish data, 
here publishers disclosed facts any way, authenticity of data 
seems to be fallacious. 
For under reporting various factors involved such as the 
project result not probably positive one, lack of data to 
support on this matter and concerned on such outcome not 
yet published Chan et al (2013), faulty assumption with no 
output, grievance on part of participants who underwent on 
trial, generated data less useful, marginal difference for 
input and output, disputes raised later concerned on 
intellectual property right or and other commercial attack, 
and needs to be faced legitimate concerns.  Once the product 
were found success rate in commercialization, spread out 
messages within short span of time, apprehension on 
commercial attack, the author widely condemned  because 
of the international law abiding bodies guarded on trade 
related problem.(intellectual property right). And other 
contention on this regards, researcher’s idea hided or 
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repelled from the competitors’ attention; however the idea 
were rebuffed to get pinnacle services to the community. 
Hilal (2014) peer reviewed articles described the 
importance of clinical trials conducted regarding orphan 
drugs, approach should be changed because of these 
diseases rarely existing, difficult to get comprehensive view 
on part of researcher, it needs to be concern, health care 
providers diligent to meet unprecedented facts, initiatives 
and subsidies from the public sector and established 
legislative policies by the regulatory authorities. Social 
media those whom genuine information passed to the 
public, not only support awareness programs but also can 
access efficient therapeutic information recently evolved. 
Here the national and transnational cooperation facilitated 
for collection of précised data, prevalence rate should be 
concluded especially on these rarely encountered diseases 
prone in certain area (Middle East). 
Benater SR (2000) provides description on number of 
factors which determine the attractiveness of clinical trial in 
developing countries as in developing countries like India, 
less cost comparative to western countries, highly 
infrastructure hospital, back grounded by professional team, 
and loopholes on existing legislative system. Here deplorable 
condition that one forced in to clinical trial triage 
impoverished one, apostle that stringent regulation and 
enforcement absolutely necessary to hospital morphing both 
in sick as well as healthy volunteers. Annas, George J (2009) 
propounded that economic advantages in India cant denied 
on clinical trial depending on the number of patients and 
investigators. Here the most sponsors enjoys 30 to 50 
percentage operating cost over similar trial in the US and 
Europe. Liquid chromatography and mass spectrometry as 
the same in worldwide, central laboratory services and other 
analytical services even do not provide any deep discounts, 
here labor cost meagerly low, which saves 10-20 percentage 
on analytical services. 
Aslam A, Ayman El-Menyar (2013) given brief description on 
clinical trial conducted in human subjects revealed that 
investigational agencies exposed fraudulent activities in 
realm of clinical trial practices conducted both by sponsors 
and on by trial investigators. Fabrication of data and even 
the providers hided negative finding for claiming in front of 
regulating authorities. While publishing clinical practices, 
and author illustrated view on declaration of Helsinki, the 
trial must be registered, public accessible data before 
recruitment on this subject, to fulfill twenty mandatory (pre 
requisite information) should be passed. Nida khan (2014) 
reviewed articles exposed downtrodden situation in 
developing countries , concerned on negligence on part of 
post research responsibilities by the  research institutes, 
once the trial completed medicines supplied as free of cost in 
industrialized countries, here advocated  for an investigation  
on existing judiciary system to implement it in a proper 
channel, here poor patient pushed in to clinical trial 
adventure, to those whom found sacrificed his/hers lives on 
uncertain things, but once the clinical trial succeeded, , it is 
shameful he/she  can’t access these medicines at affordable 
rate. Author opined at least sponsors can delivers generic 
version of this products for poor countries, present scenario 
quite different sponsors initially alliance with international 
as well as public private partnership. Once the product 
succeeded in the market, the concerned countries, ministry 
of health by international bodies (such as global alliance for 
vaccination and immunization, global fund for HIV, malaria 
and tuberculosis so on) or should be compensated cost of 
this product proportionately. Here author weighed impact 
on valuable services provided by the researcher by 
disseminating valuable information whether it is success or 
failure. The similar theorem proposed by Sisira siribaddana 
(2013) from  in Sri Lanka, there is lack ethical obligation 
facility (statutory bodies) which hastened physician industry 
relationship, recent presses release clearly supported the 
above fact, and they have been paid off 1.5 lack rupees for 
recruiting patient. He described that noncommercial clinical 
trial can carried out in academic or health care institution 
and with other collaborative individuals or groups in public 
health care system , the above statement considered as a 
suggestive method to avoid clandestine arrangement made 
in initial stage between researcher and pharmaceutical 
industries. 
However the innocent man willing to participate in clinical 
trial studies, Darzen (2007) et al based on his studies 
explained participant were enthusiastic to publish data on 
them trial conducted and expressed felicitous manner. 
Similar studies conducted by Tamer Hifnawy (2018) shows 
similar statement that on Egypt, Saudi Arabia, Sudan, and 
Lebanon clearly indicated that patient were willing to 
participate on clinical trial studies on humanitarian concern. 
However the patient opined exploited privileges on patient’s 
condition, jobless, illiterate man willing to participation 
whatever situation circumscribed, similar studies conducted 
in south India exposed similar facts,  
METHODOLOGY 
As the studies focus on health care providers, professional 
commitment, attitudes towards practicing, people concerned 
expectations as well as contributing factors on ethical 
dilemma, and also dialectical peculiarities were noticed. The 
research based on direct personal contact and also online 
reply by the respondents. For the justification, it used 
specific research tools, “questionnaire and interview guide” 
to study survey, point out that in qualitative and quantitative 
in nature, in fact questionnaire at large and interview guide 
at lesser extent to gather exhaustively bigger information in 
all 463 samples (physician – 179, Dentist 43, pharmacist 66, 
nurses 45, Researcher 52, professors-66) considered on this 
part of studies. 
In the survey design, the most important facts to design 
standardized questionnaire, it free from personal bias, 
initially data collection done by observing on consumer’s 
attitude, concerned general perception whole community in 
health care system, the researcher spend time in Dubai 
(UAE), Sohar, Muscat (Oman), in which large amount of 
international migrant met from the region of south Asia and 
middle east, and in south India, it takes four years and takes 
maximum efforts to reach in a conclusion. Here author not 
only closely inspected on attitude, and perception of people 
related on health promoting activities but also behavior of 
shoppers, and health care providers and other intermediate 
agencies (representatives, consultant agencies), systematic 
approach done throughout this studies to carry out 
functioning on  this research studies which attributed in 
quantitative and in qualitative terms. 
Sample unit 
Health care providers were professional experts being 
actively involved in clinical trial and as a policy maker, 
professors with high medical back ground, the physician as 
well as allied health workers minimum three years of 
experience included. 
Sample techniques  
For this study, simple stratified random sampling techniques 
as well as direct personal approach concerned through 
questionnaire, In this study researcher bottom out both 
primary and secondary data, the research survey limited 
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only a few of the members distributed in wild geographic 
area. There are 463 respondents are chosen using random 
sample techniques, in which lottery method used for the 
selection of respondents. 
In the first part of questionnaire were closed one, here 
participants can mark any one of the option based on 
his/hers presumption. In the second question 6 point likert 
sale considered, one in agreed and disagreed terms, and in 
last part closed one, question hinted favored circumstance, 
for immoral way of conducting clinical trial . 
Time Dimension 
The present studies were cross sectional one, as the nature 
of studies it have limitation on to conduct longitudinal 
research, repeated research articles relevant to topic 
published in different areas partially implicated failure on to 
implementation of health policy, without suggesting any 
remedial solution, data collection for this research studies 
carried over eleven months from expert members under this 
subject consideration in south Asia (India, Pakistan, 
Bangladesh and, Nepal) middle east countries (Egypt, turkey, 
Saudi, Oman, UAE, Iran, Iraq, Jordan). 
DATA ANALYSIS  
Analysis classification of Data (Demographic Profiles) 
 
 Demographic data profile almost research data interpreted, 
in certain extent it have crucial role to play based on subject 
studies, the analysis of diagram represented a total of 463 
participant in which 296 participants were found male, and 
remaining 167 respondents were found female, the 
weightage given almost same for both sex (male/female)  
Analysis classification of Data (Profession) 
the subjects related on health care, almost all section of the 
societies who served in clinical field considered on this 
subjects, here priority given to the physician because of all 
role on this relevant field subjugated (accustomed in their 
clinical practice), by them.  Even this studies under 
consideration education of participants, which reflected on 
this studies many factors like quality of participants, 
behavior of respondents, research competencies, and 
innovative capabilities.  
The analysis of above data represented different stake 
holders in health care field like physician, dentist, 
professors, researcher, pharmacist, nurses. In which overall 
179 physician in the region of South Asia (138) and 
counterpart Middle East countries (41).Dentist being 
participated on this research studies a total of 43 from south 
Asian region (32), and one from Middle East found eleven 
participants.  
And a total 78 highly experienced medical professors 
worked in familiar institutes around the globe, from the 
south Asian region (62), and one counterpart from Middle 
East countries (16), and a total of 62 well expert researches 
practicing in clinical field, from South Asian countries (44), 
from Middle East countries (8), and pharmacist who were 
well known things based on his clinical exposure, A total of 
66 pharmacist participated on this studies from south Asian 
region (40) and one from Middle East (26), one of the major 
mediator in clinical field like 45 nurses participated on this 
studies from the region of south Asia (27), counterpart from 
Middle East countries (18). 
 
  
 
The above table illustrated on experience of health care 
providers in their clinical practices. Initially a total of 520 
participants responded on this research studies, through 
online survey conducted by using Google forms 
(admaero2017@gmail.com, admaero2000@gmail.com, 
admaero2018@gmail.com,) and on by offline service 
through by personal approach. However 57 participants 
rejected due to incomplete data, and on by below three years 
experiences found. Based on subjects considered importance 
of experience in clinical fields’ minimum of three years 
Finally selected a total of 463 participants to those whom 
experience between 3 to 6 years found (201+43.19%), 
between 7 to 10 years (93+20.08%), between to 11 to 14 
(59+12.74%), between 15 to 19(52+11.23%), between 20 
and above (58+12.52%) 
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Analysis of classification of Data (knowledge on clinical trial)        
Efficacy and monitoring of adverse drug reaction conducted in which clinical trial phase? 
 
On the above picture illustrated on knowledge of clinical trial 
relevant to ADR studies conducted, here the corrected one 
found one third of participants 151(32.8%) participants, 
46(valid 10 percentages) participants revealed ignorance on 
the above statements, wrong answer made phase 
1(48+10.4%), phase 2(109+23.7%), phase 4(106+23%), 
three of them withdrawn to comment on this statement, the 
above statement partially suggested that general belief on 
pharmaceutical products well established ADR system before 
coming on to the market.  
 
 
Chart A: While reporting the finding of clinical trials, a few adverse drug reactions reported. 
Chart B: Clinical trial conducting team not providing reliable information to those administered patients (Understanding entire 
procedures & risks involved) 
Chart C: Medical professional are given substantial incentives to recruit their own patient to clinical trial 
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The above charts illustrated on clinical trial studies 
conducted in immoral ways, circumstance provides 
favorable situation, more over opportunity leaded to commit 
fraudulent activities such as clinical trial conducting team 
not providing reliable information to those administered 
patients (Understanding entire procedures & risks involved, 
out of 463 participants arrived values aggregated 234 
(strongly agreed 87*2, agreed 181*1, neither agreed nor 
disagreed 74*0, disagreed 49*1, strongly disagreed 36*2 
equal to 234,here36 person withdrawn to comment on this 
statement. choices were made on while reporting the finding 
of clinical trials, a few adverse drug reactions reported, on 
this statement shows similar manner 
(90*2+191*1+80*0+30*-1+25*-2=290) 46 person 
withdrawn to comment on this statement. and one third 
statement “Medical professional are given substantial 
incentives to recruit their own patient to clinical trial”, 
participants made declaration, aggregated values were found 
(102*2+159+1+74*0+56*-1+20*-2 equal to 267), here 40 
participants withdrawn to comment on this statement.  
Analysis of classification of data (attributes relevant to 
unethical practice of in clinical trial. 
Would you recommend the favorable condition to conduct 
clinical trials in immoral way? 
 
The above picture illustrated on finding of favorable 
situation to conduct clinical trial studies such as hospital 
privileges (54+ 11.8%), by scarcity of state and local law 
(48+10.5%), lack of ethical obligation and professional 
standards (100+21.8%), out of 463 participants on the above 
all question marked by179 participants (valid percentages 
39), more than one sixth participants withdrawn to comment 
on this statement (78+17%), here four participants not at all 
commented. 
RESULTS 
The data shows significant difference on different aspects 
muddled on immoral way of conducting clinical trial triage, 
“Efficacy and monitoring of adverse drug reaction conducted 
in which clinical trial phase?” on this statement nearly one 
third of participants made right choice, more than two third 
of the participants wrong choices made, clearly indicates less 
knowledge on relevant matters amongst the health care 
professionals, trials were conducted hush-hush way, on later 
statement confirmed the above facts, “Would you 
recommend the favorable condition to conduct clinical trials 
in immoral way?” like hospital privileges, scarcity of state 
and local law, lack of ethical obligation and professional 
standards, here one above all parameters agreed by the 40 
percentage of participants. one fourth of the participants 
opined lack of ethical obligation and professional standards 
versed on scarcity of state and local law, hinted failure on 
implementation legislative procedures, here one sixth of the 
participants emphasized on hospital privileges. 
Proceeding statement gives more clarification on the above 
statement “while reporting the finding of clinical trials, a few 
adverse drug reactions reported, Clinical trial conducting 
team not providing reliable information to those 
administered patients (Understanding entire procedures & 
risks involved, Medical professional are given substantial 
incentives to recruit their own patient to clinical trial”. Here 
more than two third of participants agreed on the above 
three statements. The statement, nearly one tenth of 
participants withdrawn to comment on this statement.  
DISCUSSION 
Studies shows significant difference on  immoral way of 
conducting clinical trial triage, “Efficacy and monitoring of 
adverse drug reaction conducted in which clinical trial 
phase?” on this statement nearly one third of participants 
made right choice, more than two third of the participants 
wrong choices made, clearly indicates less knowledge on 
relevant matters amongst the health care professionals, the 
above finding assured by the studies conducted  Waheed S, 
Siddiqui E et al (2013) on clinical trial issues, here research 
assistant usually appointed medical students or graduated 
found lack of knowledge relevant to international conference 
on Harmonization and Good clinical practice Guidelines (ICH 
GCP guidelines). As the case in India found, pharmaceutical 
industries focused on to developing countries due to 
favorable situation like low literacy, poverty, loopholes in 
existing legitimacy in clinical trial system.  Halidou Tinto, 
Ramadhani A.Noor et al (2013), recommended theoretical 
clinical practices alone  not sufficient  to ensure proper 
clinical outcomes and for facilitation of medical research, the 
situation often worsened due to high workloads on health 
care providers in peripheral settings, want to monitor 
routine checkup to validate this situation, and the risk of 
double standard keeping amongst the patients (free of cost 
services versed on cost paid services), here need to take 
practical consideration and up gradation of knowledge on 
relevant subjects especially in low middle income countries,  
The later statement confirmed the above facts, “Would you 
recommend the favorable condition to conduct clinical trials 
in immoral way?” like hospital privileges, scarcity of state 
and local law, lack of ethical obligation and professional 
standards, the above all parameters agreed by the 40 
percentage of participants. One fourth of the participant’s 
opined lack of ethical obligation and professional standards 
versed on scarcity of state and local law, hinted failure in 
implementation legislative procedures, here one sixth of the 
participants emphasized hospital privileges favored to 
conduct clinical trials in immoral ways. succeeding statement 
gives more clarification on the above statement such as 
“While reporting the finding of clinical trials, a few adverse 
drug reactions reported, Clinical trial conducting team not 
providing reliable information to those administered 
patients (Understanding entire procedures & risks involved, 
Medical professional are given substantial incentives to 
recruit their own patient to clinical trial”. Here more than 
two third of participants agreed on the above three 
statements, hesitated to comment on this statement one 
tenth of participants. 
The core principles while conducting clinical trial in human 
subjects, should be conducted ethically and on propounded 
by international guidelines (declaration of Helsinki), the 
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17% 
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Don’t know/cannot say. 
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subjects matter should be scientifically justified one, and it 
needs foreseeable and forecasted on difficulty raised in  trial 
participants,  outweighed possible risks and benefit for 
entire society, it needs approval from ethical committee or 
from institutional review boards prior to initiation to 
conduct studies in individual subjects, and complied with 
approval committees protocol, informed consent needs to be 
furnished, data communicated through by understandable 
language,  and preferred one in vernacular language  to get 
more assurance on individual subjects, the subjects followed 
and validated risk benefit ratio on individual patient, and 
prudent on later complication.  
Peter C Gotsche (2009) pear reviewed data onto counterfeit 
scientific misconduct especially noted as ghost writing 
finkelstein and Temin (in reasonable Rx solving the drug 
price crisis) opined public sector should be take 
independent, nonprofit organization for drug development. 
Schafer’s counter parted studies supported the above facts, 
research wing adjudicated and should be separated from 
commercial activities, another theorem discussed by national 
bodies to manage clinical trial in health organization (USA) 
compensation should be pay off under purview of authorized 
body, curbed access of pharmaceutical industries to direct 
influence on researchers. 
It needs to address this problem as one suggested by Ms 
Irene Schipper (SOMO Publication, 2009), on topic of Clinical 
trials in developing countries: How to protect people against 
unethical practices, described on clinical trial practices that 
one not approved in western EU, clinical trials were 
sanctioned dominant countries like china, Russia, Argentina. 
Not at all barriers for marketing as one found in EU. In 
developing countries Helsinki declaration relevant to ethical 
practices on clinical trial utterly neglected. Further 
implementation procedures through legislative and 
regulatory follow up procedures aggravated this situation. 
Memorandum passed in World health assembly 2010 by the 
organized bodies working in research and development, 
expert opined to build up a trusteeship with all countries 
contribution of 0.01 percentage of their GDP, it was rejected 
on proceeded meeting by some of the countries, the author 
hinted that financial motives and political dominance put 
certain barrier on transparency and accountability of 
existing system, lack of addressing such bodies leads to 
encourage voluntary concept system, noted in ethical 
violation by pharmaceutical industries and repercussion on 
relevant term, here denied not only quality of health service 
to reach the common man but also indirectly leaded to 
deterioration of health status, that leads to wastage of money 
too. 
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